# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the pr...
Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate ...
Oppenheimer analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform rating a...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $1...
Under the terms of the collaboration agreement, Rani and ProGen agree to share responsibilities for the development and commerc...
Maxim Group initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating and announces Price Target of $15.
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating an...
BTIG analyst Robert Hazlett maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and raises the price target from $7 t...